HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

4-(Dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-3,4,4a,5,5a,6,12,12a-octahydrotetracene-2-carboximidic acid

HCID 54671203
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
564-25-0
Standard SMILES
C[C@H]1c2cccc(O)c2C(O)=C2C(=O)[C@]3(O)C(O)=C(C(N)=O)C(=O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
InChIKey
SGKRLCUYIXIAHR-AKNGSSGZSA-N
Molecular formula
C22H24N2O8
Average molar mass
444.4 g/mol
Monoisotopic mass
444.15326573

Overview

Doxycycline (internal use) can cause developmental toxicity according to state or federal government labeling requirements.

Names & identifiers

Preferred name
4-(Dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-3,4,4a,5,5a,6,12,12a-octahydrotetracene-2-carboximidic acid
IUPAC
(4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
English name
Doxycycline
Molecular formula
C22H24N2O8
Molecular weight
444.43

Names & synonyms

DTXSID809922124-(Dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-3,4,4a,5,5a,6,12,12a-octahydrotetracene-2-carboximidic acid7164-70-7RefChem:1070088DTXCID301419281doxycycline564-25-0VibramycinDoxytetracyclineDoxycycline (anhydrous)DoxycyclinumMonodox
Show more names
doxycylineDoxycyclin hyclateDoxycyclinDOXYCYCLINE HYDRATE(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamidedoryxliviatin
DoxiciclinaDoxycycline anhydrous6alpha-Deoxy-5-oxytetracyclineVibra-tabsDoxycycline hyclate5-Hydroxy-alpha-6-deoxytetracyclineVibramycineDoxychel

Database identifiers

CAS
564-25-0、7164-70-7
PubChem CID
54671203
DTXSID
DTXSID80992212
ChEMBL
CHEMBL436921
ChEBI
CHEBI:50845
UNII
334895S862
EC Number
657-194-0
Nikkaji
J6.511K

Properties

Computed structural propertiesFilling in

XLogP
-0.7
Topological polar surface area
182 Ų
Hydrogen bond donors
6
Hydrogen bond acceptors
9
Rotatable bonds
2
Heavy atoms
32
Formal charge
0
Complexity
956

Experimental & physicochemical properties

Drugs · 3 items

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals -> Antibiotics (Tetracyclines)

Pharmaceuticals -> Listed in ZINC15

Animal Drugs · 2 items

Pharmaceuticals -> UK Veterinary Medicines Directorate List

Pharmaceuticals -> Animal Drugs -> Approved in Taiwan

Dissociation Constants3.09
Collision Cross Section · 4 items

193.16 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

197.4 Ų [M+H]+ [CCS Type: TW]

205.7 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with Waters Major Mix]

199.24 Ų [M-H]-

Physicochemical properties

Melting point
206 · 206-209°C (dec.)
Boiling point
554.44 °C · 554.44°C (rough estimate)
Density
1.3809 · 1.3809 (rough estimate)
refractive index
1.65 · 1.6500 (estimate)
storage temp.
2 · under inert gas (nitrogen or Argon) at 2-8°C
solubility
125 mg/mL · DMSO : 125 mg/mL (281.26 mM; Need ultrasonic)
pka
3.5 · pKa 3.5 (Uncertain);7.7 (Uncertain);9.5 (Uncertain)
form
Solid
color
Light yellow to brown
Water Solubility
0.63 g/L · 0.63g/L(25 ºC)
BCS Class
3 · 3,1
InChIKey
JBIWCJUYHHGXTC-AKNGSSGZSA-N
SMILES
C1(=O)[C@]2(O)[C@@]([H])([C@@H](O)[C@@]3([H])C(=C2O)C(=O)C2=C(C=CC=C2O)[C@@H]3C)[C@H](N(C)C)C(O)=C1C(N)=O
CAS DataBase Reference
564 · 564-25-0(CAS DataBase Reference)
FDA UNII
334895 S862 · 334895S862
Proposition 65 List
Doxycycline (internal use)
NCI Drug Dictionary
Vibramycin
ATC code
1 AB22,J01AA02 · A01AB22,J01AA02
EPA Substance Registry System
Doxycycline (564-25-0)
Protein binding
90 % · >90%
Excreted unchanged in urine
33 · 33-45%
Volume of distribution
0.7 · 0.7(L/kg)
Biological half-life
18 · 18 / Unchanged
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
302 · H302-H315-H312-H319-H335-H332
Precautionary statements
280 · P280-P302+P352-P312-P322-P363-P501-P264-P280-P302+P352-P321-P332+P313-P362-P264-P270-P301+P312-P330-P501-P261-P271-P304+P340-P312-P264-P280-P305+P351+P338-P337+P313P
Hazardous Substances Data
564 · 564-25-0(Hazardous Substances Data)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Safety data

Signal word
Warning
Symbol(GHS)
GHS07
Hazard statements
H302-H315-H312-H319-H335-H332
Precautionary statements
P280-P302+P352-P312-P322-P363-P501-P264-P280-P302+P352-P321-P332+P313-P362-P264-P270-P301+P312-P330-P501-P261-P271-P304+P340-P312-P264-P280-P305+P351+P338-P337+P313P
Hazardous Substances Data
564-25-0(Hazardous Substances Data)

Chemistry & industry

Pharmacology

ATC CodeJ01AA02
Protein BindingWhile there is limited information available, tetracyclines bound to plasma proteins in varying degree.
Pharmacodynamics · 1 item

Doxycycline and other tetracyclines are mainly bacteriostatic and are thought to exert antimicrobial effects by the inhibition of protein synthesis. They suppress the growth of bacteria or keep them in the stationary phase of growth. Tetracyclines have antimicrobial spectrum of activity against a variety of gram-positive and gram-negative microorganisms. Cross-resistance of these microorganisms to tetracyclines is a common occurrence. As it is a highly lipophilic drug, doxycycline crosses multiple membranes of target molecules. Doxycycline shows favorable intra-cellular penetration, with bacteriostatic activity against a wide range of bacteria. Doxycycline also exhibits antiparasitic properties and anti-inflammatory actions. Its anti-inflammatory effects were investigated in various inflammatory skin conditions, such as bullous dermatoses and rosacea.

Mechanism of Action · 1 item

Protein synthesis is essential for survival and functioning of cells, including bacteria. Doxycycline inhibits bacterial protein synthesis by allosterically binding to the 30S prokaryotic ribosomal subunit. The drug blocks the association charged aminoacyl-tRNA (aa-tRNA) with the ribosomal A site, which is the acceptor site on the mRNA-ribosome complex. Doxycycline ultimately impedes the elongation phase of protein synthesis and halts the production of essential proteins for bacterial survival and functioning. Doxycycline mediates anti-inflammatory actions by preventing calcium-dependent microtubular assembly and lymphocytic proliferation, thereby inhibiting leukocyte movement during inflammation. It also inhibits nitric oxide synthase, which is an enzyme that produces nitric oxide, an inflammatory signaling molecule.

Biological Half-LifeThere is limited information available.
Metabolism/MetabolitesThere is limited information available.
Absorption, Distribution and Excretion · 4 items

Doxycycline is virtually completely absorbed after oral administration with a bioavailability of ranging from 73-95%. Following an oral dose of 500 mg, the Cmax of 15.3 mg/L was reached in four hours. Following a 200 mg dose, normal adult volunteers averaged peak serum levels of 2.6 mcg/mL of doxycycline at 2 hours, decreasing to 1.45 mcg/mL at 24 hours. While a high-fat meal lowers Cmax and the rate of absorption, the effect is not clinically significant.

Tetracyclines, including doxycycline, are concentrated in bile by the liver and excreted in the urine and feces at high concentrations and in a biologically active form. Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with a creatinine clearance of about 75 mL/min. This percentage may fall as low as 1-5%/72 hours in individuals with a creatinine clearance below 10 mL/min.

There is limited information available.

Population pharmacokinetic analysis of sparse concentration-time data of doxycycline following standard of care intravenous and oral dosing in 44 pediatric patients two to 18 years of age showed allometrically -scaled clearance (CL) ranging from 3.27 to 3.58 L/h/70 kg.

Uses & manufacturing

Use ClassificationPharmaceuticals -> Animal Drugs -> Approved in Taiwan
Applications · 4 items

UsesDoxycycline is used for the same indications as other antibiotics of the tetracycline series; however, it belongs to the group of long-lasting tetracyclines. In some cases it is more active with respect to a number of organisms, and is better tolerated than other tetracyclines. Synonyms of this drug are azudoxat, codidoxal, eftapan, vibramycin, and others.

UsesDoxycycline is a semi-synthetic tetracycline prepared by hydrogenolysis of oxytetracycline to remove the 6-hydroxy group. Although the synthesis was reported in 1958, it was not released for use until 1967. Doxycycline, together with minocycline, is regarded as a ‘third generation’ tetracycline largely replacing the analogues and pro-drugs produced in the early 1960s for mainstream antibiotic applications. Like all tetracyclines, doxycycline shows broad spectrum antibacterial and antiprotozoan activity and acts by binding to the 30S and 50S ribosomal subunits, blocking protein synthesis. Doxycycline has been extensively cited in the literature with over 10,000 references.

Usestetracycline antibiotics

General DescriptionA more recent addition to the tetracycline group of antibioticsavailable for antibacterial therapy is doxycycline,α-6-deoxy-5-oxytetracycline (Vibramycin), first reportedby Stephens et al. in 1958. It was obtained first in smallyields by a chemical transformation of oxytetracycline, butit is now produced by catalytic hydrogenation of methacyclineor by reduction of a benzyl mercaptan derivative ofmethacycline with Raney nickel. The latter processproduces a nearly pure form of the 6α-methyl epimer. The6α-methyl epimer is more than 3 times as active as itsβ-epimer.169 Apparently, the difference in orientation of themethyl groups, which slightly affects the shapes of the molecules,causes a substantial difference in biological effect. Also, absence of the 6-hydroxyl group produces acompound that is very stable in acids and bases and that hasa long biological half-life. In addition, it is absorbed verywell from the GI tract, thus allowing a smaller dose to be administered.High tissue levels are obtained with it, and unlikeother tetracyclines, doxycycline apparently does not accumulatein patients with impaired renal function.Therefore, it is preferred for uremic patients with infectionsoutside the urinary tract. Its low renal clearance may limit itseffectiveness, however, in urinary tract infections.Doxycycline is available as a hydrate salt, a hydrochloridesalt solvated as the hemiethanolate hemihydrate, and amonohydrate. The hydrate form is sparingly soluble in waterand is used in a capsule; the monohydrate is water insolubleand is used for aqueous suspensions, which are stable for upto 2 weeks when kept in a cool place.

Upstream & downstream products

Upstream raw materials

OxytetracyclineHydrogen fluorideHydrogenMETHACYCLINE
Additional notes · 1 item

DefinitionChEBI: Tetracycline in which the 5beta-hydrogen is replaced by a hydroxy group, while the 6alpha-hydroxy group is replaced by hydrogen. A semi-synthetic tetracycline antibiotic, it is used to inhibit bacterial protein synthesis a d treat non-gonococcal urethritis and cervicitis, exacerbations of bronchitis in patients with chronic obstructive pulmonary disease (COPD), and adult periodontitis.

Related reactions

1 records
New reaction record
HRID 1076077 reaction equation
HRID 1076077As productAs reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes